C. Diff. Infections

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Lumen Bioscience
Lumen BioscienceWA - Seattle
1 program
1
LMN-201 Anti-toxin B VHH-1Phase 11 trial
Active Trials
NCT04893239Completed12Est. Feb 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Lumen BioscienceLMN-201 Anti-toxin B VHH-1

Clinical Trials (1)

Total enrollment: 12 patients across 1 trials

NCT04893239Lumen BioscienceLMN-201 Anti-toxin B VHH-1

Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies

Start: Aug 2021Est. completion: Feb 202212 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space